Highlights
- Managing nasal polyps requires a comprehensive approach to improve quality of life.
- Biologic therapies show promise but face challenges in cost and accessibility.
Overview of Nasal Polyps
Nasal polyps are benign inflammatory growths arising from chronic rhinosinusitis with nasal polyps (CRSwNP), causing symptoms like nasal obstruction, rhinorrhea, and loss of smell. They often recur and are linked to systemic inflammatory conditions such as asthma and aspirin-exacerbated respiratory disease (AERD). Diagnosis involves endoscopy and imaging to assess disease extent. Effective management requires addressing both the polyps and underlying inflammation to prevent recurrence and improve quality of life.
Treatment Approaches
Management combines medical and surgical methods to reduce symptoms and inflammation. Topical intranasal corticosteroids are first-line therapy, effectively decreasing polyp size and symptoms but may cause nasal irritation. Systemic corticosteroids, biologics (e.g., dupilumab, omalizumab, mepolizumab), and endoscopic sinus surgery are options for severe or refractory cases. Aspirin desensitization benefits patients with AERD, while antibiotics are reserved for bacterial infections. Herbal medicine and acupuncture show anecdotal promise but require further study.
Surgical and Medical Treatments
Endoscopic sinus surgery removes polyps and improves sinus ventilation but does not cure underlying inflammation; about 20% of patients need revision surgery within five years. Postoperative corticosteroid sprays and avoidance of irritants help prevent recurrence. Topical corticosteroids remain central to management, sometimes combined with short courses of oral steroids. Biologics target specific inflammatory pathways, offering significant symptom relief but are costly and require injections. Other treatments under investigation include antileukotrienes and furosemide.
Effectiveness and Safety
Topical corticosteroids are effective, safe, and accessible for long-term use. Biologics have shown substantial improvements in polyp size and symptoms in clinical trials but are limited by cost and administration challenges. Surgery improves symptoms and quality of life but carries risks of complications and recurrence. Herbal and complementary therapies have limited evidence and are not standard treatments.
Factors Influencing Treatment Selection
Treatment choice depends on disease severity, patient comorbidities, and prior responses. Imaging guides staging and therapeutic decisions. Topical corticosteroids are preferred initially; systemic steroids and biologics are reserved for more severe cases. Biologics are effective across polyp sizes and comorbidities like asthma and AERD but may not achieve full remission in all patients. Antibiotics address acute infections, while antifungals remain controversial. Quality of life assessments assist in monitoring treatment response.
Long-term Management
Preventing recurrence and controlling symptoms are key goals. Continued use of topical corticosteroids is recommended, with cautious use of oral steroids during exacerbations. Emerging treatments like furosemide and macrolide antibiotics show potential in reducing recurrence. Biologics offer promising long-term benefits but require further evaluation regarding safety and cost. Self-care measures, including avoiding irritants and adherence to therapy, support maintenance.
Impact on Quality of Life
Effective treatment improves nasal airflow, reduces anosmia, and enhances daily functioning. Biologics notably improve quality of life in severe cases and may reduce the need for surgery. Systemic corticosteroids and aspirin desensitization can also alleviate symptoms but carry risks. Complementary therapies might aid some patients, though evidence is limited.
When to Seek Specialist Care
Referral to an otolaryngologist is advised for significant symptoms or inadequate response to initial treatments. Specialist evaluation includes endoscopy to confirm diagnosis and guide management. Surgery may be necessary for refractory or recurrent polyps. Early specialist involvement facilitates personalized treatment plans and better long-term outcomes.
Future Directions
Research focuses on achieving clinical remission and reducing recurrence through biologics targeting Th2 inflammation, improved imaging techniques, and adjunct pharmacological therapies like macrolides. Complementary therapies such as herbal medicine and acupuncture are being explored but lack robust evidence. Future priorities include optimizing treatment combinations, long-term safety evaluation of biologics, and enhancing clinician education to improve patient care.
The content is provided by Avery Redwood, Direct Bulletins